{"id":"cefozopran","rwe":[],"tags":[{"label":"cefozopran","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DE03","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cefozopran"],"offLabel":[],"synonyms":["cefozopran"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefozopran","explanation":"Imagine the bacterial cell wall as a brick wall. Cefozopran blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse. This makes it difficult for the bacteria to survive and multiply.","oneSentence":"Cefozopran works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefozopran exerts its antibacterial effect by competitively inhibiting the action of penicillin-binding proteins (PBPs), which are essential for the synthesis of the bacterial cell wall. This inhibition prevents the cross-linking of peptidoglycan chains, ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/551","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOZOPRAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:20:34.735101","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-21T10:58:33.462650+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"cefepime","drugSlug":"cefepime","fdaApproval":"1996-01-18","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"cefozopran","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefepime","brandName":"cefepime","genericName":"cefepime","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1LG87K28LW","CHEBI":"CHEBI:3502","INN_ID":"6918","UMLSCUI":"C0246584","ChEMBL_ID":"CHEMBL1276663","KEGG_DRUG":"D01052","DRUGBANK_ID":"DB13667","PUBCHEM_CID":"9571080","IUPHAR_LIGAND_ID":"12054","MESH_SUPPLEMENTAL_RECORD_UI":"C070918"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.7 hours","clearance":"2.1 mL/min/kg","fractionUnbound":"0.74%","volumeOfDistribution":"0.24 L/kg"},"publicationCount":182,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DE03","allCodes":["J01DE03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CEFOZOPRAN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefozopran is a third-generation cephalosporin antibiotic, classified as a small molecule drug. It is a synthetic derivative of cephalosporin, but its original developer and current owner are unknown. Cefozopran is not FDA-approved, and its approved indications are also unknown. It has a half-life of approximately 1.7 hours, but its bioavailability and commercial status are not well-documented. As a result, its availability and safety profile are uncertain.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-21T10:58:33.462650+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}